Recent Updates
Recently added Catalysts
AMLX Positive Sentiment

Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

Monday, August 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Amylyx Pharmaceuticals is set to announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide, targeting Post-Bariatric Hypoglycemia, on August 18, 2026. The announcement will be followed by a conference call hosted by the senior management team. This trial represents a crucial step in the company's clinical development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of topline results indicates progress in clinical development.
  • The Phase 3 trial could lead to significant advancements in treatment.
  • Management engagement through a conference call shows transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.4%
average across 3 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
AMX0035
Phase 3 · Amyotrophic Lateral Sclerosis

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time

Frequently Asked Questions

When will Amylyx announce the trial results?

Amylyx will announce the topline results on August 18, 2026.

What is the focus of the LUCIDITY trial?

The LUCIDITY trial focuses on Avexitide for treating Post-Bariatric Hypoglycemia.

How can I access the conference call?

Dial +1 (888) 880-3330 for U.S. & Canada or +1 (646) 357-8766 internationally.

What time is the conference call scheduled?

The conference call is scheduled for 8:00 a.m. ET.

ShareAdd on Google
Tags: AMLX Viatris Investor Conferences Healthcare Amylyx Pharmaceuticals Avexitide Post-Bariatric Hypoglycemia clinical trial
Last updated: Aug 17, 2026

Biotech snapshot

Cash runway
$251M liquidity · $15M/mo burn
~16 mo
Low dilution risk
Lead asset
AMX0035Phase 3
Amyotrophic Lateral Sclerosis →

Catalyst track record

+167%
best trade around AMLX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AMLX.

See every catalyst's timing & PoA →